Ascendis Pharma A (ASND) Asset Writedowns and Impairment (2024 - 2025)
Ascendis Pharma A (ASND) posted Asset Writedowns and Impairment of -$2.6 million for Q4 2025, down 132.79% sequentially from $7.9 million in Q1 2025.
Powered by 
Analysis
Ascendis Pharma A (ASND) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Ascendis Pharma A has reported Asset Writedowns and Impairment for 1 years, with the latest figure at -$2.6 million in Q4 2025.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to -$2.6 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$2.6 million (down 132.79% YoY) and the FY2025 annual result came in at $6.1 million, changed N/A from the prior year.
- Asset Writedowns and Impairment retreated to -$2.6 million in Q4 2025 per ASND's latest filing, from $7.9 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $7.9 million in Q1 2025 and troughed at -$2.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ascendis Pharma A | 16.39 Bn | 15.45 Bn | 362.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 81.57 Mn |
| Mar 31, 2025 | 7.90 Mn |
| Dec 31, 2024 | 66.22 Mn |